Sanofi's profit for the third quarter saw a significant increase due to strong demand for seasonal vaccines and the continued growth of its leading skin and asthma treatment, Dupixent.
The company's earnings per share, excluding certain items, were €2.86 ($3.10), surpassing analysts' expectations.
The surge in earnings was driven by earlier-than-expected sales of its influenza and respiratory syncytial virus vaccines. This increase in vaccine sales demonstrates Sanofi's proactive approach to addressing seasonal health needs, positioning the company favorably in the competitive pharmaceutical market.